| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d29ca880e97e861cddc010dad35bf8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecaa5e666925f3e003e2846f878bfba8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bce9134bca222b0560cd00791671a62 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-813 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
1996-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf9cb267df6233699d6c7ae3f65e0211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3412c58accd720be2c1cbf2f74992b63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a7ec802e9a798bb4d1755ea72a9e722 |
| publicationDate |
1996-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9626442-A1 |
| titleOfInvention |
Early detection of prostate cancer (cap) by determining a ratio involving prostate specific antigen (psa) and human glandular kallikrein (hgk-1) concentrations |
| abstract |
The invention relates to a bioaffinity assay of prostate-specific antigen (PSA) comprising the measurement of either the concentration of total PSA (PSA-T), the concentration of free form of PSA (PSA-F) or the concentration of PSA complexed to alpha-1-antichymotrypsin (PSA-ACT), PSA-T being the sum of PSA-F and PSA-ACT. According to the invention, additionally the concentration of human glandular kallikrein (hGK-1) is measured. The concentrations of PSA-T and hGK-1 can be measured in one single assay or in separate assays. The sum of the concentrations of PSA-T and hGK-1 is used to determine the ratio a) PSA-F/(PSA-T + hGK-1) and/or b) PSA-ACT/(PSA-T + hGK-1). Both of these ratios are shown to have an outstanding clinical utility for the discrimination of prostate cancer and benign prostatic hyperplasia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6645770-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6309816-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6479263-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6235486-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6093796-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6103237-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9846993-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9945398-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9846993-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6013471-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0050899-A1 |
| priorityDate |
1995-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |